New naltrexone shot takes on vivitrol in early trial

NCT ID NCT05620940

Recruiting now Disease control Sponsor: Inventage Lab., Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-stage trial tests a new long-acting naltrexone injection (IVL3004) against the approved drug Vivitrol in 40 healthy men. The goal is to compare how the drug moves through the body and check for safety. It does not yet test if it helps treat opioid or alcohol dependence.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: naltrexone long-acting injection
What this could lead to: If successful, this could lead to a new long-acting naltrexone option for treating opioid or alcohol dependence, potentially offering similar benefits to Vivitrol.
What could go wrong: This is a very early Phase 1 study in only 40 healthy men, not patients. It only checks drug levels and safety, not whether it actually works for addiction. Many early-stage drugs fail to show benefit later.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALCOHOL DEPENDENCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alcohol abuse alcohol dependence multiple sclerosis opiate dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALCOHOL DEPENDENCE MULTIPLE SCLEROSIS OPIOID DEPENDENCE

Contacts and locations

Locations

Nucleus Network
RECRUITING

Herston, Queensland, 4006, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.